u/Cryptocashish

The author argues VKTX is not competing on peak obesity efficacy but is positioning to win the post-commoditization obesity market where persistence, adaptability, and payer economics dominate. VK2735's induction-to-maintenance dosing, multi-cadence flexibility, and oral/injectable optionality are designed to maximize treated months per patient and reduce churn under real-world behavioral variability. This structure could generate greater economic value than more potent but brittle alternatives as the obesity market matures. Main stated risks include step-down dosing degrading efficacy, oral tolerability not improving persistence, physician resistance to multi-cadence complexity, payer refusal of regimen flexibility, and manufacturing/commercialization failure.